Özmen, Mehmet MahirZülfikaroğlu, BarışÖzmen, FüsunMoran, MünevverÖzalp, NecdetSeçkin, Selda2021-05-212021-05-212021: Özmen MM, Zülfikaroğlu B, Özmen F, Moran M, Özalp N, Seçkin S. D2 vs D2 plus para-aortic lymph node dissection for advanced gastric cancer. Turk J Surg 2021; 37 (1): 49-58.2564-68502564-7032https://doi.org/10.47717/turkjsurg.2020.4931https://hdl.handle.net/20.500.12713/1747Abstract Objective: Gastric cancer is a common malignancy worldwide. Effective treatment by interdisciplinary cooperation is important, and surgery still plays an important role. Material and Methods: In a ten-year period, 355 patients were diagnosed to have gastric cancer. One hundred and sixty-two patients with a median (range) age of 58 (23-83) years were eligible for the study. There were 107 patients in D2 and 55 patients in D2 lymphadenectomy plus para-aortic lymph node (PALN) dissection group. The two groups were compared in terms of complications, morbidity, mortality and long-term survival. Results: Length of stay was 12 (8-34) days for D2 and 14 (8-42) days for D2 plus PALND. Total number of operative mortality was 8/162 (5%), and it was not different between the groups. Twenty patients (18%) had complications in D2 group and 9 (17%) patients in D2 plus PALND group. Overall survival was also similar between the groups, but patients with T3-T4 tumors, patients with stage IIIA and IIIB disease had better survival with D2 plus PALN dissection. We found that the depth of invasion, PLN, ratio (PLN/TLN), stage and LND were all prognostic variables. Conclusion: This study showed that D2 plus PALN dissection for advanced gastric cancer can be performed as safely as a standard D2 dissection by experienced surgeons without increasing postoperative morbidity and mortality. D2 plus PALN dissection should be preferred in the advanced stage of the disease (IIIA-IIIB) as it increases the rate of survival.eninfo:eu-repo/semantics/openAccessAdvanced Gastric CancerD2 LymphadenectomyD2 Lymphadenectomy Plus Para-Aortic Lymph Node DissectionMorbidityMortalityPrognosis Extended D2Surgical-TreatmentSurvival BenefitWestern PatientsD-2 ResectionsRisk-FactorsLymphadenectomySurgeryD3GastrectomyArticle3714958WOS:0006449161000102-s2.0-85108799118N/A10.47717/turkjsurg.2020.4931N/A503804